Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer

Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer is a phase 2/3, randomised interventional study registered as NCT07034326 by Kong Fanming, with a registry enrolment figure of 405 participants, started 2025-01-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: Electroacupuncture combined with immunotherapy; Zilongjin tablet combined with immunotherapy; Immunotherapy. Conditions listed: Non-Small Cell Lung Cancer; Electroacupuncture; Immune Checkpoint Inhibitors. Primary outcome: Disease free survival(DFS). Lung eligibility wording from the registry: "* (1) Non-tumor patients with stage II, IIIA, IIIB (N2) non-small cell lung cancer diagnosed by pathology or cytology after surgery; (2) driver mutations negative patients; (3) Postoperative adjuvant chemotherapy was received for 1 to 4 cycles;(4)conforms to two qi syndrome of traditional Chinese me". Sites: China. No results are recorded here; the registry entry is the source.